The majority of time patients with bipolar disorder are ill, they are depressed. There are few FDA approved treatments for bipolar depression and all of them are second-generation antipsychotics which carry a high side effect burden. Clinical experience has suggested that TMS might be effective for bipolar depression. This presentation will review the existing literature on the efficacy of TMS for bipolar depression and present the findings from a two-center open-label prospective trial of TMS in bipolar depression including type I and type II patients.
At the end of the presentation, attendees will gain an understanding of the existing literature on the efficacy of TMS for bipolar depression and learn additional insights from an examination of a two-center open-label trial.
Presented by Scott Aaronson, M.D.
Dr. Scott Aaronson is director of clinical research programs, director of transcranial magnetic stimulation services, and chair of the medical executive committee at Sheppard Pratt Health System in Baltimore, Maryland. He is an Adjunct Professor in the Department of Psychiatry at the University of Maryland School of Medicine. Dr. Aaronson specializes in treatment-resistant affective disorders. He is a thought leader in the areas of biological psychiatry, diagnosis, and the integration of somatic and psychological therapies, and is the principal investigator for multiple studies on the development of novel therapies for mood and anxiety disorders. Dr. Aaronson is a valued speaker and educator and frequently lectures both regionally and nationally on mood disorders, including the integration of biological and psychotherapies, complex mood disorders, psychoeducation, and the development of new therapies. Much of his research work and publications center on the development of various neurostimulation paradigms including Transcranial Magnetic Stimulation, Vagus Nerve Stimulation, Direct Current Stimulation, and synchronized TMS to treat severe mood disorders. Recently, he has begun research into the use of psychedelics in mood disorders including three studies looking at psilocybin in various presentations of depression. He is a member of the board of directors of the Clinical TMS Society and the American Society for Clinical Psychopharmacology. Dr Aaronson earned his MD with honors from Harvard Medical School. He completed a residency in psychiatry at McLean Hospital, as well as a fellowship in sleep physiology at Harvard Medical School. He is a Distinguished Life Fellow of the American Psychiatric Association and a Fellow of the American College of Psychiatrists.